Hanmi Pharmaceutical Enters Exclusive Partnership with Laboratorios Sanfer
Hanmi Pharmaceutical is making significant strides toward expanding its global reach with efpeglenatide, a groundbreaking treatment for obesity and metabolic diseases. The company has recently entered into an exclusive distribution agreement with Mexican pharmaceutical leader Laboratorios Sanfer. This partnership encompasses not just efpeglenatide but also the Dapalon Family of diabetes medications, which include Dapalon Tablet and Dapalon Duo SR Tablet.
Details of the Partnership
Under the terms of this strategic agreement, Hanmi will supply its innovative obesity treatment and diabetes medications, while Laboratorios Sanfer will oversee regulatory approvals, marketing, and distribution throughout Mexico. This collaboration shows great promise, particularly as Mexico grapples with high obesity and diabetes rates, making it an opportune market for these therapies.
Addressing a Growing Health Crisis
Currently, the prevalence of obesity in Mexico stands at 36.86%, with diabetes affecting 16.4% of the population. This stark reality highlights the need for effective treatments that extend beyond mere weight loss and target comprehensive blood glucose management. The alliance between Hanmi and Sanfer not only reflects confidence in the scalability of efpeglenatide but also emphasizes its strategic importance in tackling these critical health challenges in Mexico.
About Laboratorios Sanfer
Established in 1941, Laboratorios Sanfer has risen to become Mexico's largest privately held pharmaceutical company. Renowned for its robust sales and distribution network across Latin America, Sanfer leverages its in-house research and development capabilities to maintain a competitive edge in the pharmaceutical market. With operations spanning over 20 countries in Latin America and the United States, Sanfer recently bolstered its stature within the biopharmaceutical sector by acquiring Probiomed.
Future Perspectives and Collaborative Opportunities
The partnership is anticipated to evolve beyond the initial scope, potentially introducing additional product lines and joint marketing initiatives targeting a wider array of metabolic disease treatments. Ricardo Amtmann, the CEO of Sanfer, expressed enthusiasm about the collaboration, emphasizing its potential to enhance medical accessibility and treatment quality. He remarked, "Our vision as a pharmaceutical leader is firmly centered on improving patient outcomes through high-quality and innovative products. With healthcare costs being a significant burden in Mexico, this partnership is timely and essential."
Commitment to Innovation
From Hanmi's perspective, this partnership signifies a crucial milestone in demonstrating their formulation capabilities and competitiveness in global markets. Jae-hyun Park, CEO of Hanmi Pharmaceutical, stated, "We see this agreement not only as an endorsement of our innovative spirit but also as an opportunity to significantly contribute to health improvement in Mexico. As the government focuses on enhancing healthcare standards, our therapies align perfectly with these objectives.”
Regulatory Progress and Future Plans
On the regulatory front, Hanmi recently submitted an application for efpeglenatide to the Ministry of Food and Drug Safety and is positioning itself for further development. Notably, the company plans to expand efpeglenatide's indications to include diabetes, with a projected obesity treatment approval expected in the latter half of 2026, followed by diabetes approval set for 2028. This ambitious timeline underscores Hanmi's commitment to advancing healthcare solutions.
In conclusion, the collaboration between Hanmi Pharmaceutical and Laboratorios Sanfer is set to pave the way for significantly improved health management strategies in Mexico, targeting two of the most pressing health concerns of our time: obesity and diabetes. As both companies continue to innovate and expand their capabilities, they are poised to make notable contributions to healthcare.
Frequently Asked Questions
What is the main goal of the Hanmi and Sanfer partnership?
The primary goal of the partnership is to enhance the availability of efpeglenatide and diabetes treatments in Mexico, addressing the urgent health concerns of obesity and diabetes.
What is efpeglenatide?
Efpeglenatide is a GLP-1 class medication developed for treating obesity and managing metabolic diseases.
How will the partnership affect patients in Mexico?
This collaboration aims to improve patient access to innovative and effective treatments for obesity and diabetes, resulting in better health outcomes.
What is the significance of the obesity and diabetes rates in Mexico?
Mexico's high rates of obesity and diabetes highlight a critical public health crisis that necessitates effective medical interventions, such as the ones provided by Hanmi and Sanfer.
When is afpeglenatide expected to be approved in Mexico?
Approval for efpeglenatide is anticipated in the second half of 2026, with diabetes indications planned for 2028.
